JCM
NVCR icon

JS Capital Management’s NovoCure NVCR Stock Holding History

JS Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,100
Closed -$815K – 192
2020
Q1 		$815K Buy
+12,100
New +$956K 0.1% 30
2019
Q4 		– Sell
-3,333
Closed -$249K – 148
2019
Q3 		$249K Buy
+3,333
New +$267K 0.03% 86

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

JS Capital Management's NVCR Position: Q2 2020 in Review

JS Capital Management sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 12,100 shares — an estimated $815K sold.

JS Capital Management first reported a position in NVCR in Q3 2019 and held it in 2 quarters. The position peaked at $815K in Q1 2020. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

  • JS Capital Management reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
  • JS Capital Management sold 12,100 NovoCure shares in Q2 2020, an estimated $815K.
  • JS Capital Management first reported a position in NovoCure in Q3 2019 and held it in 2 quarters.
  • JS Capital Management's NovoCure position peaked at $815K in Q1 2020.
  • 264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on JS Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.